AMGN vs GILD
Amgen Inc. and Gilead Sciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | AMGN | GILD |
|---|---|---|
| Revenue | $36.8B | $29.4B |
| Net income | $7.7B | $8.5B |
| Gross margin | 67.2% | 78.8% |
| Net margin | 21.0% | 28.9% |
| Return on equity | 106.1% | 40.5% |
| Diluted EPS | $14.23 | $6.78 |
| Dividend / share | $9.66 | $3.16 |
| Payout ratio | 66.5% | 47.0% |
| Free cash flow | $8.1B | $9.5B |
| Equity | $8.7B | $22.7B |
| Net debt / equity | 5.25× | 0.77× |
| Current ratio | 1.14× | 1.55× |
| Revenue CAGR 5y | 7.6% | 3.6% |
| Profit CAGR 5y | 1.2% | 133.3% |
AMGN bills 1.2× the revenue of GILD, and GILD keeps more of each dollar of revenue as profit (28.9% against 21.0%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | AMGN | GILD |
|---|---|---|
| FY2025 | $36.8B | $29.4B |
| FY2024 | $33.4B | $28.8B |
| FY2023 | $28.2B | $27.1B |
| FY2022 | $26.3B | $27.3B |
| FY2021 | $26.0B | $27.3B |
| FY2020 | $25.4B | $24.7B |
| FY2019 | $23.4B | $22.4B |
| FY2018 | $23.7B | $22.1B |
| FY2017 | $22.8B | $26.1B |
| FY2016 | $23.0B | $30.4B |
Net income by year
Bottom line
| Fiscal year | AMGN | GILD |
|---|---|---|
| FY2025 | $7.7B | $8.5B |
| FY2024 | $4.1B | $480.0M |
| FY2023 | $6.7B | $5.7B |
| FY2022 | $6.6B | $4.6B |
| FY2021 | $5.9B | $6.2B |
| FY2020 | $7.3B | $123.0M |
| FY2019 | $7.8B | $5.4B |
| FY2018 | $8.4B | $5.5B |
| FY2017 | $2.0B | $4.6B |
| FY2016 | $7.7B | $13.5B |
Advertisement
AdSense · Rectangle 336×280
More in this industry